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a b s t r a c t
Human babesiosis is an emerging tick-borne parasitic disease and blood transfusion-transmitted infec-
tion primarily caused by the apicomplexan parasite, Babesia microti. There is no licensed vaccine for B.
microti and the development of a reliable serological screening test would contribute to ensuring the
safety of the donated blood supply. The recent sequencing of the B. microti genome has revealed many
novel genes encoding proteins that can now be tested for their suitability as subunit vaccine candidates
and diagnostic serological markers. Extracellular proteins are considered excellent vaccine candidates
and serological markers because they are directly exposed to the host humoral immune system, but
can be challenging to express as soluble recombinant proteins. We have recently developed an approach
based on a mammalian expression system that can produce large panels of functional recombinant cell
surface and secreted parasite proteins. Here, we use the B. microti genome sequence to identify 54 genes
that are predicted to encode surface-displayed and secreted proteins expressed during the blood stages,
and show that 41 (76%) are expressed using our method at detectable levels. We demonstrate that the
proteins contain conformational, heat-labile, epitopes and use them to serologically profile the kinetics
of the humoral immune responses to two strains of B. microti in a murine infection model. Using sera
from validated human infections, we show a concordance in the host antibody responses to B. microti
infections in mouse and human hosts. Finally, we show that BmSA1 expressed in mammalian cells can
elicit high antibody titres in vaccinated mice using a human-compatible adjuvant but these antibodies
did not affect the pathology of infection in vivo. Our library of recombinant B. microti cell surface and
secreted antigens constitutes a valuable resource that could contribute to the development of a serolog-
ical diagnostic test, vaccines, and elucidate the molecular basis of host-parasite interactions.
 2018 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Parasites of the genus Babesia are prevalent apicomplexan
pathogens transmitted by ticks and infect many mammalian and
avian species (Yabsley and Shock, 2013). Tick-borne diseases have
a major impact on both human and animal health, with annual
economic losses to the global cattle industry estimated at over
US$ 17 billion (de Castro, 1997; Homer et al., 2000); consequently,
there is a drive to understand the biology of these understudied
parasitic diseases. Several Babesia spp. parasites are zoonotic and
there are a growing number of reported incidences of human infec-
tion, several of which fall outside the established endemic regions
of the US northeastern and upper midwestern states (Westblade
et al., 2017), including Europe and Asia (Ord and Lobo, 2015).
The increase in reported cases has consequently led the Center
for Disease Control (USA) to classify Babesia microti as a nationally
notifiable disease since 2011 (Herwaldt et al., 2011). Human
babesiosis is primarily caused by the parasite, B. microti, and is
most commonly tick transmitted; however, it can also be acquired
following transfusion of infected blood and occasionally transpla-
cental passage (Levin and Krause, 2016). The infection is charac-
terised by fever and haemolytic anaemia, and can result in death
from complications such as heart failure, respiratory distress and
pulmonary oedema in severe cases (Vannier et al., 2015). The
antibiotics atovaquone and azithromycin are frontline treatments
but resistance to these drugs has been reported (Wormser et al.,
2010). In the US, babesiosis is the most frequently reported trans-
fusion transmitted microbial infection, and the systematic testing
of donated blood has been strongly advocated (Levin and Krause,
2016; Jajosky and Jajosky, 2017). Prevention is therefore limited
to questionnaire-based deferral which is largely ineffective as
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infections are often cryptic and asymptomatic in healthy individu-
als. Added to this, the parasite can persist in donor blood, and
because patients who receive blood transfusions are often
immunocompromised (neonates, the elderly, and those in post-
operative care) these circumstances increase the likelihood of seri-
ous pathological outcomes from the transmission of infected blood
such that mortality can be as high as 20% (Herwaldt et al., 2011).
There is no licensed vaccine for B. microti, but recent progress in
the molecular understanding of how other apicomplexan parasites,
particularly the blood stages of the malaria parasite Plasmodium
falciparum, recognise and invade host erythrocytes has provided
fresh impetus in the development of vaccines that target the blood
stages of these parasites (Bustamante et al., 2017; Cowman et al.,
2017).
Babesia spp. parasites are comparatively understudied zoonotic
pathogens, and B. microti is a distinct and early-arising clade, his-
torically referred to as the small Babesia due to the morphology
of the parasite in the parasitized erythrocyte, and is most closely
related to Theileria spp. parasites (Cornillot et al., 2012). Babesia
microti is transmitted by hard-bodied ixodid ticks with the pre-
dominant vector being the deer tick (Ixodes scapularis), and the nat-
ural hosts are rodents, mainly the white-footed mouse (Peromyscus
leucopus) in the endemic regions of the northeastern US (Vannier
et al., 2015). Babesia microti infection occurs while the tick takes
a blood meal. Similar to related Babesia parasites, the transmitted
sporozoite is thought to recognise and invade erythrocytes
directly. Once inside the erythrocyte, B. microti matures into the
trophozoite form, completes its asexual reproductive cycle to
develop into four merozoites, before lysing the erythrocyte so that
the released blood-stage parasites can invade further erythrocytes.
Erythrocyte invasion is an essential step in the parasite life-cycle
and, as the merozoite stage is directly exposed to circulating host
antibodies, targeting invasion by eliciting antibodies to essential
parasite invasion ligands is considered a rational approach for vac-
cine design; however, because very little is known regarding the
molecular basis of B. microti erythrocyte invasion, there are a lim-
ited number of possible targets. Babesia microti does contain ortho-
logues of the known molecular components that are important for
erythrocyte invasion in the more widely-studied malaria parasite
P. falciparum, including the AMA-1 and RON-2 proteins (Ord
et al., 2016; Wang et al., 2017), implying the conservation of at
least some aspects of the invasion mechanism although B. microti
lacks clear orthologues of the EBL and RH protein families that
are central to the invasion machinery of P. falciparum, suggesting
that species-specific innovations have also evolved (Cornillot
et al., 2012).
The genome of B. microti has been sequenced recently and is
remarkable due to its small size of only 6.4 Mbp, encoding just
3500 proteins (Cornillot et al., 2012; Silva et al., 2016). It is
thought that the B. microti genome evolved by significant gene loss,
possibly because its cellular tropism became restricted to erythro-
cytes in its mammalian hosts (Cornillot et al., 2012). With its com-
pact genome, B. microti perhaps contains the minimal molecular
machinery required for erythrocyte invasion which, together with
the availability of a tractable rodent infection model, represents an
opportunity to expand our understanding of the fundamental
mechanisms of erythrocyte invasion and explore the vulnerability
of the system to inhibition by vaccine-elicited antibodies. Identify-
ing the direct interactions between the proteins that are secreted
and displayed at the surface of P. falciparum with host receptors
has been important in furthering our molecular understanding of
how other parasites invade erythrocytes, and this has led directly
to the identification of new vaccine targets (Bartholdson et al.,
2013). Expressing these proteins in a recombinant form provides
experimental tractability; however, extracellular proteins are chal-
lenging to express recombinantly because their hydrophobic
transmembrane-spanning regions make them difficult to solubilise
in solvents that retain their native folding, and they often contain
structurally critical disulfide bonds that are sometimes not faith-
fully formed by some heterologous expression systems (Crosnier
et al., 2013).
We have developed an approach based on a mammalian
expression system that enables production of large panels of
secreted recombinant proteins consisting of the entire predicted
ectodomains of parasite proteins that are likely to retain their
native folding. We have used this approach to compile protein
libraries that represent the cell surface receptor repertoire and
secretome of the blood stages of P. falciparum (Crosnier et al.,
2013; Zenonos et al., 2014) and Plasmodium vivax (Hostetler
et al., 2015). We have shown that these proteins can retain their
biochemical binding functions and immunoreactivity (Crosnier
et al., 2011; Wanaguru et al., 2013; Osier et al., 2014). Here, we
compile a library of recombinant proteins representing the pre-
dicted cell surface receptor repertoire of the blood stage of B.
microti and use them to characterise the host antibody response
to infections in both humans and a murine infection model. Finally,
we show that high titres of antibodies elicited against the B. microti
major coat protein do not affect parasitaemia in mice. These pro-
teins form an important resource for the Babesia research
community.
2. Materials and methods
2.1. Babesia microti parasite and mouse strains
All animal experiments were performed in accordance with
local ethical and UK Home Office regulations according to the UK
Animals (Scientific Procedures) Act 1986. Babesia microti was
obtained from BEI Resources, 10,801 University Boulevard, Manas-
sas, VA 20110-2209, USA: Greenwich Yale Lab Strain 1 (LS1), a tick
isolate (ATCC: PRA-401) and Nan_Hs_2011, (N11-50), a clinical iso-
late from blood collected from a babesiosis patient in Nantucket,
USA, in 2010 (PRA-399). Babesia microti strains were maintained
by serial passage in immunodeficient SCD (NOD.Cg-Prkdc) mice.
Vaccine and infection challenge studies were conducted in BALB/
c inbred mice.
2.2. Selection and synthesis of a library of B. microti cell surface and
secreted proteins
Predicted protein coding regions (3609) from B. microti were
collated from the B. microti (R1) genome (Cornillot et al., 2012)
and existing database sequences identified in expression cloning
studies (Lodes et al., 2000; Nishisaka et al., 2001; Homer et al.,
2003; Yokoyama et al., 2003; Luo et al., 2011; Cao et al., 2013).
These protein sequences were analysed for the presence of pre-
dicted transmembrane (TM) domains, glycosylphosphatidylinosi-
tol (GPI) anchor and signal peptide (SP) sequences using Phobius
(290 proteins were SP-positive and 622 proteins were SP-
negative, TM-positive) (Kall et al., 2004), PredGPI (62 proteins)
(Pierleoni et al., 2008) and SignalP v4.1 (252 proteins) using the
default D-cut-off value (Petersen et al., 2011), respectively. Pro-
teins predicted to be membrane-embedded but for which the ecto-
domain was unlikely to consist of a contiguous protein sequence
such as multi-pass membrane proteins that lacked a signal peptide
and those with sequence homologies to proteins localising to
membranes of intracellular organelles such as the endoplasmic
reticulum or mitochondria were excluded. Systematic protein sim-
ilarity searches to ensure inclusion of orthologues of known cell
surface and secreted proteins from the blood stages of other
apicomplexan parasites including Babesia and Plasmodium spp.
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identified 13 orthologues. Searches for proteins containing
domains of interest including thrombospondin and EGF-domain
identified 11 proteins that were included in the library and the
orthologous protein sequence used to aid manual annotation. RNA-
seq transcriptome data from mice and hamster blood stage B.
microti infections were used to exclude 75 genes not transcribed
during the blood stages (Silva et al., 2016). For those selected
genes, the loci were manually annotated using transcriptome data
aligned to the B. microti genome. In brief, transcriptome data was
retrieved from the European Nucleotide Archive (ENA) (accession
numbers: PRJNA218917-PRJNA218922) and mapped to the refer-
ence genome using TopHat (Trapnell et al., 2009) with a minimum
intron length of 20 bp, as B. microti genes were found to include
many small introns. Artemis (Rutherford et al., 2000) was used to
visualise data for manual annotation of gene architecture. The
sequences corresponding to the entire ectodomains were identi-
fied by using software tools to predict the location of the signal
peptides, transmembrane and GPI-anchor regions as above. Syn-
thetic gene constructs corresponding to these sequences were
made by gene synthesis (GeneartAG, Germany), essentially as
described (Crosnier et al., 2013). Briefly, signal peptides were
removed since a high-scoring exogenous signal peptide from a
mouse antibody kappa light chain is encoded on the expression
plasmid (Crosnier et al., 2010); sequences were codon-optimised
for expression in human cells; and N-linked glycosylation consen-
sus sites (N-X-S/T) were modified by substituting the serine or
threonine residue with an alanine residue to prevent the inappro-
priate addition of large glycans which are likely to be absent from
B. microti since, as for Plasmodium spp. parasites, the genes encod-
ing enzymes required for N-glycosylation are absent from the B.
microti genome (Lombard, 2016). The coding sequences were
cloned into a mammalian expression plasmid containing the rat
Cd4 domains 3 and 4 antigenic tag, an enzymatic biotinylatable
sequence, and 6-His tags as previously described for Plasmodium
parasite protein libraries (Crosnier et al., 2013). All B. microti
expression plasmids and full sequences are available from Addgene
(www.addgene.org/express). Where proteins were used for immu-
nisation, the coding sequences were subcloned into a vector lack-
ing the Cd4 tag to aid quantification of specific antibody responses.
2.3. Recombinant protein expression, ELISA and purification
Proteins were expressed by transient transfection in
suspension-grown HEK293E (Durocher et al., 2002) and HEK293-
6E cells (Loignon et al., 2008), essentially as described (Kerr and
Wright, 2012). 6-His-tagged proteins were purified from spent tis-
sue culture supernatant using either a 1 mL HisTrap HP column (GE
Healthcare, UK) using an ÄKTAxpress or ÄKTApure instrument (GE
Healthcare), or using Ni-NTA-Agarose (Jena Bioscience, Germany);
50 lL of Ni-NTA-Agarose bead suspension was added per 50 mL of
cell culture supernatant, incubated overnight at 4 C with rotation
before purification according to the manufacturer’s instructions. To
determine protein integrity, 2 to 6.5 mL of transfection supernatant,
or 2 mg of purified protein was resolved by SDS-PAGE under reduc-
ing conditions, transferred to nitrocellulose membrane (Invitrogen,
UK), blocked with 2% BSA in Tris-buffered saline/0.1% Tween-20
(TBST), and probed with 0.02 mg/mL of streptavidin-horseradish
peroxidase (Jackson Immunoresearch, Europe Ltd., UK) diluted in
2% TBS-BSA. Biotinylated proteins were detected with Supersignal
West pico chemiluminescent substrate (Perbio, UK). Expression
levels in Table 1 are given as a guide as batch-to-batch variability
is observed using this approach, but as a guide, ‘‘high” corresponds
to 5–50 lg/mL, ‘‘medium” (0.5–5 lg/mL) and ‘‘low” (0.005–0.5 lg/
mL). Protein levels were quantified by ELISA after immobilising
dilutions of the biotinylated Cd4-tagged protein in individual wells
of streptavidin-coated microtitre plates and using the mouse anti-
rat Cd4 monoclonal antibody (OX68) as a detection antibody and
an anti-mouse-alkaline phosphatase conjugate as a secondary anti-
body (Sigma, UK), essentially as described (Crosnier et al., 2013). To
quantify elicited host antibody titres, proteins were immobilised
directly on streptavidin-coated plates as above, or heat treated
for 10 min at 80 C prior to immobilisation on the streptavidin-
coated plate. Sera was diluted 1:1000 in 2% (w/v) BSA-PBS and
total host IgG and IgM antibody binding was detected using the
appropriate alkaline phosphatase conjugated secondary antibody.
Seropositivity is defined as a mean response greater than 3 S.D.
above the control protein. Human sera were obtained from individ-
uals who were diagnosed as infected by B. microti by Giemsa stain-
ing and/or PCR (18s rRNA) and indirect fluorescence assay using
sera from infected hamsters under Institutional Review Board
approval from the New York Blood Center, USA, project number:
618-10. Antibody binding was detected using HRP-conjugated
anti-human secondary antibody and 3,30,5,50-tetramethylbenzi
dine substrate.
2.4. Immunisation, B. microti infection and quantification of
parasitaemia by flow cytometry
Nine-week-old female BALB/c mice were immunised i.p. with
100 mg of recombinant protein in sterile PBS adjuvanted with alhy-
drogel 1:1 by volume (Invivogen, France) according to the manu-
facturer’s instructions, followed by two further boosts of 20 mg.
The protein sequence of the B. microti R1 BmSA1 vaccine antigen
differs from the LS1 challenge strain at a single amino acid
(R133T) (Silva et al., 2016). Peripheral blood samples were taken
to determine the antibody titre approximately 16 days following
the final immunisation. Mice were rested for 4 weeks prior to
infection with 1  107 infected erythrocytes from heparinized
blood taken from an infected donor SCD mouse (at day 9 of infec-
tion during the ascending parasite growth phase), diluted in sterile
dPBS (with Ca2+/Mg2+, Sigma) immediately prior to infection chal-
lenge. Parasitaemia was quantified by flow cytometry using blood
biopsies taken from a peripheral vessel in 50 mL of Alsever’s solu-
tion (Sigma) in a 96-well microtitre plate and fixed for greater than
24 h with 100 mL of 0.01% v/v glutaldehyde at 4 C. For parasite
quantification, samples were centrifuged, resuspended in dPBS
(with Ca2+/Mg2+, Sigma). Samples (50 mL) were resuspended in
1:5000 SYBR Green I (Invitrogen, UK) in dPBS and incubated for
1 h at 37 C before washing and resuspending in 200 mL of dPBS.
Samples were analysed in a BD Fortessa 2 (BD Biosciences, UK)
equipped with a high-throughput sampler. SYBR Green I was
detected by a 530/30 filter and autofluorescence of erythrocytes
with a 450/50 filter. A BD FACS Diva (BD Biosciences, UK) was used
to collect 10,000 events for each sample, gated on the erythrocyte
population. The data were analysed using FlowJo software.
3. Results
3.1. A library of recombinant B. microti blood stage cell surface and
secreted proteins
To identify proteins expressed on the surface of the blood stage
merozoite, we systematically analysed 3609 predicted protein cod-
ing regions from B. microti: 3565 from the published B. microti R1
genome (Cornillot et al., 2012; Silva et al., 2016), and an additional
44 that had been previously identified in expression cloning stud-
ies (see Section 2.2). Proteins likely to be embedded within the par-
asite plasma membrane or secreted were identified based on the
presence of either a predicted transmembrane sequence or
N-terminal signal peptide which resulted in a list of 346 proteins.
These proteins were manually examined and those that were
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predicted to be located in intracellular organelles, encode small
peptides (<10 kDa), or spanned the membrane multiple times
without a predicted contiguous N-terminal extracellular region,
were excluded. Genes not expressed during the blood stages of
infection were excluded by mapping transcriptome data from
blood stage mouse infections (Silva et al., 2016) to the B. microti
R1 strain reference genome sequence. This list was augmented
by searching the B. microti genome for homologues of merozoite
surface proteins from other apicomplexan parasites that have been
shown to have a role in invasion, and for the presence of protein
domains that have roles in adhesion such as thrombospondin-
like and EGF domains. From this short list, we again used the tran-
scriptome data to manually refine the gene structures resulting in
54 genes that included 15 encoding a protein with one or more
transmembrane-spanning regions, 12 containing a C-terminal
hydrophobic sequence for the addition of a GPI lipid anchor, and
27 that had no obvious way of being tethered to a membrane
and so were predicted to be secreted (Table 1).
Table 1
Details of the library of Babesia microti cell surface and secreted proteins. Each protein is grouped according to its predicted architecture (multi-spanning transmembrane protein,
single-pass transmembrane protein, glycosylphosphatidylinositol-anchored or secreted). A description of the protein is provided, if known, together with the amino acid
numbering of the regions expressed, an indication of the level of expression (Exp.; see Section 2.3; n.d. = not detected), the predicted molecular mass of the protein including
protein tags, and the plasmid number in the Addgene plasmid repository.
Accession Protein Description Region Exp. MM (kDa) Addgene
Transmembrane – multipass
BMR1_01g00210 Cysteine Rich Modular Protein, CRMP S22-I1938 low 239 107665
BMR1_03g04695 Rhoptry neck protein 2 D31-G1257 low 162 107666
BMR1_01g03335 Conserved, similar to T-cell immunomodulatory protein in Theileria spp. E21-S665 med 98 107667
BMR1_02g04181 Conserved, putative nuclear fusion protein T19-S287 low 55 107668
BMR1_01g03280 Putative copper/ion transporter, BMN1-20 G23-T427 med 70 107669
Transmembrane – single
BMR1_04g07915 Serine and proline-rich protein S21-P992 n.d. 131 107670
BMR1_01g02975 Conserved, putative Thrombospondin-related protein 3 V23-P358 high 62 107671
BMR1_03g01156 Apical merozoite antigen 1 (AMA-1) A39-G529 low 79 107672
BMR1_04g08630 Unknown N29-G728 high 102 107673
BMR1_03g02090 Erythrocyte membrane-associated plasmodium like protein K27-M482 n.d. 75 107674
BMR1_01g00985 Conserved, unknown E24-L952 low 128 107675
BMR1_03g04335 Conserved, unknown G26-T1079 n.d. 143 108000
BMR1_03g00437 Conserved, unknown L20-I1451 med 187 108001
BMR1_04g06950 Conserved, unknown T16-I545 med 86 108002
BMR1_01g01210 Nicalin A37-A590 n.d. 89 108003
GPI-anchored
BMR1_02g04260 GPI9, BMN1 family G24-S260 med 51 108004
BMR1_03g00785 BmSA1, GPI12, BMN1-9 G37-S308 high 55 108005
BMR1_04g07810 BmGPI19, Sexual stage antigen, Pfam s48/45 S25-S753 low 107 108006
BMR1_04g09190 Unknown, EGF-domain containing protein E24-V190 med 43 108007
BMR1_02g04275 GPI10, N1-21a, BMN1 family G24-P289 low 55 108008
BMR1_01g00435 GPI4, 24 tandem repeat protein H24-L648 med 95 108009
BMR1_01g01875 GPI5, Sexual stage antigen, Pfam s48/45 A18-S862 n.d. 120 108010
BMR1_01g00425 GPI2, B. microti-specific L23-S490 high 77 108011
BMR1_04g05790 GPI18, acid phosphatase H19-S360 high 63 108012
BMR1_01g00430 GPI3, B. microti-specific A19-S516 high 80 108013
BMR1_03g00790 GPI13 B. microti-specific K23-A297 high 56 108023
BMR1_03g01685 GPI14, conserved, unknown, S16-A209 n.d. 47 108014
BMR1_03g03430 GPI17, conserved, unknown V23-S434 low 70 108015
Secreted
BMR1_04g07535 Maltese cross antigen N1-15 A27-H2396 low 287 108016
BMR1_01g00095 Conserved, unknown F16-N376 low 66 108017
BMR1_01g01510 Unknown S27-A451 med 72 108019
BMR1_01g03475 Unknown A22-S313 low 56 108020
BMR1_01g00945 Unknown S21-N773 low 109 108021
BMR1_03g02875 Unknown Y17-S446 n.d. 77 108022
BMR1_03g04855 BMN2 family S19-V271 high 53 108024
BMR1_03g00690 Unknown I23-L349 high 62 108025
BMR1_03g04550 Conserved, unknown A20-P139 high 38 108026
BMR1_04g05295 Unknown H24-T575 med 88 108027
BMR1_02g00320 Sporozoite microneme protein 2 R21-N879 low 120 108028
BMR1_02g00615 Cell-traversal protein, putative R21-I173 high 42 108029
BMR1_01g02875 MAC/Perforin domain containing protein I21-E614 n.d. 91 108030
BMR1_02g00700 Conserved, unknown N21-S338 n.d. 61 108031
BMR1_03g03090 LCCL domain-containing protein E14-L1572 n.d. 200 108032
BMR1_03g00020 BMN2 family M1-K474 low 82 108033
BMR1_04g09435 Conserved, unknown K19-F322 high 59 108034
BMR1_04g08470 Conserved, unknown R18-S362 n.d. 65 108035
BMR1_03g02515 LCCL domain-containing protein, CCp2 L21-L1599 low 200 108036
BmR1_04g07470 Sporozoite invasion-associated protein 1 L28-G952 low 130 108035
BMR1_01g02876 Unknown K21-G357 n.d 61 108038
BMR1_03g02385 Cathepsin C D21-T503 med 80 108040
BMR1_02g04075 Conserved, unknown Q24-P572 n.d. 90 108041
BMR1_01g02031 Rhoptry neck protein 4, RON4 K17-T1428 n.d. 185 108116
BMR1_02g02691 High molecular weight rhoptry protein 2, RhopH2 I20-N1330 n.d. 176 108042
BMR1_03g01540 Unknown L21-T419 med 68 108043
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The B. microti proteins were produced as soluble recombinant
forms using a mammalian expression system that was previously
successful in expressing a panel of blood stage proteins from Plas-
modium spp. parasites and shown to retain antigenic activity and
extracellular binding functions (Crosnier et al., 2013). The entire
predicted ectodomains were defined as the full-length sequence
for secreted proteins, and for those proteins which are predicted
to be tethered to the plasma membrane through either a trans-
membrane region or GPI-anchor, the sequence was truncated just
prior to these sequences (Table 1). Babesia, similar to Plasmodium
spp. parasites, appear to lack the full complement of enzymes
required for N-linked glycosylation, and so all potential N-linked
glycosylation consensus sequences were mutated to prevent the
addition of large glycans when expressed in mammalian cells
(Lombard, 2016). The coding regions were made by gene synthesis
which permitted codon optimization for high level expression in
human cells and cloned into a plasmid which contained an efficient
secretion signal peptide sequence, a C-terminal enzymatically
biotinylatable peptide sequence and hexa-his tags for immobilisa-
tion and purification. Proteins were expressed by transient trans-
fection of suspension-grown HEK293 cells (Durocher et al., 2002).
Of the 54 proteins in the library, 41 (76%) were secreted at
detectable levels which ranged considerably in yield (Table 1).
These parameters are very similar to other apicomplexan parasite
protein libraries produced using this approach (Crosnier et al.,
2013; Hostetler et al., 2015). Interestingly, the proteins which were
not detectably expressed included those that are predicted to be
rhoptry-localised (RON4 and RhopH2) and the orthologues of these
proteins from P. falciparum proteins also failed to express in this
system (Crosnier et al., 2013), suggesting these proteins require
parasite-specific chaperones for functional expression. Proteins
were analysed by western blotting to verify that the proteins were
produced at their expected molecular mass and to determine their
integrity (Fig. 1). Essentially all proteins were detected as a single
band at their expected mass, with the exception of the major sur-
face antigens BMR1_03g00020 and BMR1_01g00210, which were
poorly expressed and migrated quicker than expected, suggesting
these proteins are proteolytically processed; similarly, some of
the higher molecular mass proteins showed evidence of proteolytic
processing which is sometimes observed with this expression
system (Galaway et al., 2017). The major coat protein, BmSA1
(BMR1_03g00785), migrated slightly slower than its predicted
mass, which may be due to the presence of highly repetitive acidic
amino acids in this protein. Together, these data demonstrate that
panels of B. microti cell surface and secreted proteins can be
expressed as secreted recombinant proteins in a mammalian
expression system.
3.2. The B. microti blood stage library proteins are immunoreactive
and contain conformational epitopes
There are very few known biochemical activities for B. microti
proteins and so to systematically determine whether the recombi-
nant proteins within our library were folded and contained
conformational epitopes, we asked whether the proteins were
immunoreactive to sera from a chronically infected host, with the
rationale that antibody responses that are able to control the pathol-
ogy of the infection will generally recognise the parasite proteins in
their folded, native conformation. Forty-one proteins from the
library were expressed as enzymatically biotinylated proteins, their
expression levels normalised and then captured in individual wells
of streptavidin-coated microtitre plates before probing them with
immune sera from experimentally-infected BALB/c mice. To
determine if the host antibodies were recognising conformational
epitopes, we denatured the proteins by heat-treatment before
immobilising the proteins via their biotin tag. In total, 16 proteins
were immunoreactive including BMR1_01g02975
(Thrombospondin-related protein 3), BMR1_04g08630,
BMR1_01g00985, BMR1_03g00785 (BmSA1), BMR1_03g03430
(GPI17), BMR1_04g07535 (maltese cross antigen), which have been
shown previously to be highly immunoreactive (Yokoyama et al.,
2003; Luo et al., 2011; Cornillot et al., 2016; Silva et al., 2016)
(Fig. 2). Two immunoreactive transmembrane proteins,
BMR1_01g02975 (Thrombospondin-related protein 3) and
BMR1_04g08630, which contain a vWA domain and putative
Duffy-binding protein like domain (pfam12361), both reveal
conformation-dependent and independent epitopes.
BMR1_01g03280, a multipass protein, where a partial open reading
frame (ORF) was identified previously as BMN1-20 by serological
expression cloning using patient sera (Lodes et al., 2000), is highly
immunoreactive and likely contains conformational epitopes; inter-
estingly, this immunoreactivitywasnotdetectedusing recombinant
proteins expressed in Escherichia coli. Weak immunoreactivity is
seen for AMA-1 (BMR1_03g01156) and RON2 (BMR1_03g04695),
which are orthologues of important invasion proteins in other api-
complexans (Silva et al., 2016).
3.3. Antibody titres to B. microti blood proteins increase rapidly
following infection, and are maintained during chronic infection
We next sought to establish the specificity and kinetics of the
acquired antibody response across the panel of recombinant pro-
teins during experimental B. microti infection. Characterising
antigens for detection of early and late or chronic infection in mice
allows us to infer utility in blood donation screening, where
Fig. 1. A library of soluble recombinant cell surface and secreted Babesia microti proteins. Recombinant B. microti proteins from cell culture supernatant were normalised and
resolved by SDS–PAGE under reducing conditions, blotted and biotinylated proteins detected using streptavidin-horseradish peroxidase. High molecular mass proteins were
purified prior to SDS-PAGE. All proteins contain a C-terminal rat Cd4 tag (25 kDa) and were enzymatically monobiotinylated during expression.
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individual donor infection profiles are likely to exhibit more varia-
tion than clinical samples where individuals are symptomatic. In
experimental infections of immunocompetent BALB/c mice, para-
sitaemia increased rapidly before peaking at approximately
2 weeks; after which, parasitaemia dropped rapidly to become
cryptic by around 3 weeks p.i. Immunocompetent humans are also
able to effectively control parasitaemia, although the kinetics of
infection are more varied (Westblade et al., 2017). To determine
the kinetics and inter-individual variability of the acquired anti-
body response, we quantified the immunoreactivity to the antigens
during the ascending phase of parasitaemia in individual mice. Five
mice were infected with B. microti Greenwich Lab strain 1 (LS1)
and blood biopsies taken at days 4, 8, 12 and 15 when animals typ-
ically reach the peak of parasitaemia. We observed a rapid and
immunoreactive antibody response to several antigens that corre-
lated with the expected timing of the control of the infection.
Heterogeneity in the profile and magnitude of response was
observed in this highly controlled experimental infection using
in-bred mice (Fig. 3A, B). Some individuals were able to raise an
antibody response to all immunoreactive antigens, whereas others
exhibited immunoreactivity for only a subset. Reactivity to the
immunogenic antigens remained high during the cryptic phase of
infection at days 34 and 125 after initial infection (Fig. 3A, B).
A further consideration in immunoassay development is strain
specificity, with antigens that are immunoreactive to antibodies
elicited by different strains ideally required for useful diagnosis.
The protein library was based on the genome sequence from the
B. microti reference strain R1 which was isolated from a human
patient thought to have been infected in Nantucket (Stahl et al.,
2018); however, the R1 strain genome has been recently shown
to represent a different lineage from other clinically relevant
strains found in the New England (USA) area (Silva et al., 2016).
As LS1 was originally isolated from a rodent, we felt it important
to verify immunoreactive immunogens in a clinical isolate. Five
mice were experimentally infected with B. microti N11-50, a strain
isolated from a human babesiosis patient in 2010, and again blood
biopsies taken on days 4, 8, 12 and 15 p.i. and the antibody
responses to proteins within the panel quantified. We observed a
broadly similar profile of immunoreactivity to our antigen panel.
This demonstrates that, at least between these two strains of B.
microti, the same proteins elicit high-titre antibody responses
and can be detected using the protein sequence taken from the
genome reference strain.
3.4. The profile of antibody responses to B. microti infection is
correlated between humans and mice
The antigens within our panel of recombinant proteins repre-
sent possible serological antigenic biomarkers for human B. microti
infections. To profile the antibody responses in humans, we tested
sera from three human B. microti infections from New York (USA).
These samples all were validated as positive by PCR/IFA as well as
Giemsa staining for sample POS1 (1% parasitaemia). The
immunoreactivity of the sera to a protein panel containing 20 of
the most highly expressed antigens was quantified by ELISA
(Fig. 4). As expected, the samples showed individual heterogeneity,
but 14 antigens were positive in at least two of the samples, with
BmSA1 (BMR1_03g00785), BMN1-20 (BMR1_01g03280), GPI17
(BMR1_01g01510), positive in all samples. These data show that
while there is some inter-individual variability in human antibody
responses to B. microti infections, the profile of antibody responses
largely correlates between mice and humans.
3.5. The B. microti major coat protein adjuvanted in alhydrogel does
not affect the pathology of murine infections
The profiling of sera from both B. microti-infected humans and
mice across our panel of antigens identified the major coat protein
BmSA1, a protein that is localised to the merozoite membrane
(Manet al., 2017), as a highly immunoreactive antigen. Becauseboth
humanandmurine hosts,when fully immunocompetent, are able to
control B. microti infections, these antibody responses may be asso-
ciated with controlling parasite multiplication, making BmSA1 a
strong subunit vaccine candidate. To test this, we expressed BmSA1
as a secreted recombinant protein in HEK293 cells and purified it
from spent tissue culture supernatant (Fig. 5A). To elicit high anti-
body titres, recombinant proteins are usually administered with
adjuvants, but because strong adjuvants can act as general stimula-
tors of the immune response they may cause ‘‘non-specific” protec-
tive effects (Awate et al., 2013); to mitigate any possible adjuvant
Fig. 2. The Babesia microti blood stage library proteins are immunoreactive and contain conformational epitopes. The immunoreactivity of the recombinant B. microti proteins
was determined by ELISA using sera from BALB/c infected with B. microti LS1 strain. Soluble biotinylated proteins were captured on streptavidin-coated microtitre plates
either with or without heat treatment (80 C for 10 min) before adding an alkaline-phosphatase-conjugated secondary antibody to quantify immunoreactivity. Seropositivity
is defined as mean response greater than 3 S.D. above the control protein with absorbance >0.15. Seropositive antigens are marked with an asterisk and bars represent
mean ± S.D.; n = 3.
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effects we used alhydrogel, a human-compatible adjuvant. Using
this approach, we were able to elicit relatively high antibody titres
to both BmSA1 and a control antigen, with endpoint dilution titres
greater than 1:500,000 (Fig. 5B). Again, to avoid any confounding
adjuvant effects, we also ‘‘rested” the vaccinated animals for
4 weeks after the final immunisation before challenging with B.
microti LS1 strain parasites (Fig. 5C). The BmSA1-vaccinated group
showed no difference from the control immunised group, demon-
strating BmSA1 may not be an effective B. microti vaccine when
adjuvanted in human-compatible adjuvants (Fig. 5D).
Fig. 3. Profiling the immunoreactivity and kinetics of the host humoral antibody response to two different strains of Babesia microti using a panel of recombinant B. microti
proteins. (A and B) The kinetics and magnitude of antibody responses to each protein within the library were determined by ELISA from sera taken from individual mice
experimentally infected with the LS1 strain of B. microti. Monobiotinylated recombinant proteins were captured on streptavidin-coated plates and antibody responses
quantified by ELISA using blood biopsies taken from five individual mice at days 4, 8, 12, and 15 p.i. Responses in individual mice are represented by a different colour and
compared with non-infected control sera (grey line). Two post-parasite clearance data points from days 34 and 125 using pooled sera are shown (black squares). Data points
represent means ± S.D.; n = 3. The antigens are segregated in those that are strongly (A) and weakly (B) immunoreactive. (C) The antibody responses in mice infected with a
different clinical isolate of B. microti (N11-50) are broadly similar. Data shown are from sera samples pooled from five mice. The kinetics of antibody responses in individual
mice infected with the N11-50 strain of B. microti correlate well with the responses of mice infected with the LS1 strain. Data points represent means ± S.D.; n = 3.
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4. Discussion
Here, we have used the genome sequence of B. microti R1 strain
to compile a panel of recombinant proteins that represents the
repertoire of cell surface and secreted proteins for the blood stage
antigens of B. microti. We have focussed on extracellular proteins
because they are directly accessible to the host immune system
and thus are considered attractive vaccine targets and serological
diagnostic markers. The protein library was produced using a
mammalian expression system which promotes the formation of
structurally critical posttranslational modifications required for
the native folding of many extracellular proteins. This approach
ensures the proteins contain a greater number of epitopes, max-
imising target identification for diagnostic assay development
and eliciting a broad spectrum of antibodies for vaccine studies.
While it is possible that secreted ectodomains expressed in a
heterologous expression system will not adopt the same structure
as found on the parasite membrane, this approach has been suc-
cessfully applied in the study of the cell surface and secreted blood
stage antigens of another apicomplexan parasite, P. falciparum,
showing utility in seroepidemiology (Osier et al., 2014), systematic
malaria vaccine testing (Bustamante et al., 2017), and identifica-
tion of host receptors (Crosnier et al., 2011; Bartholdson et al.,
2012; Crosnier et al., 2016). Here, we report a similar success rate
with 75% of candidates selected, expressed at detectable levels. It
is possible that the number of expressed proteins could be
increased by domain boundary optimisation or reannotation, as
inaccuracies in the gene models often leads to no or poor expres-
sion. Unusually for apicomplexans, B. microti genes contain many
small introns which increases the chance of errors in automated
gene structure prediction (Silva et al., 2016) which can be
improved by manual annotation.
Babesia microti is now the most commonly reported
transfusion-transmitted microbial infection in the US with a sero-
prevalence of up to 2.5% in the general population from endemic
regions (Levin and Krause, 2016). The potential problem is not
restricted to the US, with pockets of human babesiosis caused by
B. microti reported in Germany and Switzerland (Hunfeld et al.,
2002). An inherent challenge for blood donation services in tack-
ling transfusion-transmitted babesiosis is that healthy infected
donors are typically asymptomatic so deferment by questionnaire,
the existing method of screening, is largely ineffective. Recent
studies have shown that the systematic testing of donated blood
from endemic regions is an effective way of preventing
transfusion-transmitted infections (Moritz et al., 2016). Diagnostic
and screening methods are based on low throughput hamster
infection, microscopy or immunofluorescence assay and PCR,
which requires controlled environments and specialised training
(Levin and Krause, 2016). An ELISA-based assay has considerable
advantages, such as being amenable to both low and high through-
put screening, and uses equipment available in many routine diag-
nostic laboratories. Recent progress towards developing a
serological diagnostic assay has used a mixture of four
chemically-synthesised peptides derived from the BMN1 family
of B. microti antigens, which has been tested in a human blood
donor setting (Levin et al., 2014), and screening parasite surface
antigens (Silva et al., 2016), including GPI-anchored proteins
(Cornillot et al., 2016) expressed in E. coli. Our findings confirm
that the major surface antigen BmSA1 is a highly immunogenic
protein and additionally show that all immunoreactivity was lost
upon heat treatment of the protein, demonstrating that the vast
majority of elicited antibodies recognise conformation-specific epi-
topes. This suggests that a folded protein produced in mammalian
cells may contain more informative epitopes and therefore be a
sensitive diagnostic antigen. In addition to BmSA1, we also identi-
fied several immunoreactive antigens which included two with
recognisable protein domains: BMR1_01g02975
(Thrombospondin-related protein 3), and BMR1_04g08630, which
contains a vWA and putative Duffy-binding protein like domain.
These proteins have not been previously characterised as potential
diagnostic antigens and thus inclusion of these proteins in a sero-
logical diagnostic test may improve the sensitivity and specificity
of testing. Consistent with the lack of genetic diversity observed
between the genome sequences of different B. microti strains, we
observed few polymorphisms in the genes encoding the protein
in our library, including those that were highly immunoreactive
(Silva et al., 2016). We observed that the antibody responses to
these antigens varied in individual infections, both in mice and
humans, and further work will be required to determine if these
correlate with infection parameters such as parasitaemia,
immunocompetence of the host, and stage of the disease.
Here, we have started to characterise antigens for detection of
early and late or chronic infection. In donor blood testing, individ-
ual donor infection profiles are likely to exhibit more variation
than clinical samples where individuals are, by definition, symp-
tomatic (Levin and Krause, 2016). It is also important to evaluate
if a serological approach can distinguish between active and
resolved infections, as there is a cost implication of deferring
non-infective donors who have been exposed previously to B.
microti. In experimental infections of immunocompetent BALB/c
mice, parasitaemia increases rapidly before peaking at approxi-
mately 2 weeks, after which parasitaemia drops rapidly to become
cryptic by around 3 weeks p.i. To determine the kinetics and inter-
individual variability of the acquired antibody response, we quan-
tified the immunoreactivity to the antigens during the ascending
phase of parasitaemia in individual mice and observed heterogene-
ity in the serological responses within individuals. This suggests
that the reliance on a single diagnostic antigen may lead to false
negative diagnoses, and so future work will therefore ascertain
whether an optimised smaller subset of this B. microti protein
panel will be informative in a serological diagnostics setting.
There has been an increase in the incidence of human babesio-
sis in the last decade and development of resistance to frontline
antibiotics, high rates of drug failure and poor drug tolerance has
led to renewed interest in the development of a safe and effective
vaccine (Westblade et al., 2017). The broad host range of B. microti
is a major advantage towards the development of a vaccine as the
rodent model can be used for testing the candidacy of different
antigens. A major challenge in vaccine development has been the
Fig. 4. Immunoreactivity to Babesia microti proteins in humans correlate with those
in mice. Recombinant monobiotinylated B. microti proteins were immobilised on
streptavidin-coated microtitre plates and the immunoreactivity of sera from
verified human infections was quantified by ELISA. Bar charts show mean ± S.D.;
n = 3.
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translation of vaccine efficacy from experimental laboratory ani-
mals to humans because some candidates that exhibit strongly
protective effects in mice have only limited or no efficacy when
tested in humans. One possible reason for this is the common
use of experimental adjuvants such as complete/incomplete Fre-
und’s that are strong immune stimulators that may confound any
vaccine-specific effects. Indeed, here, we report no in vivo protec-
tive effect of the major surface coat protein, BmSA1, despite elicit-
ing a high titre antibody response using alhydrogel, which is a
weak but human-compatible adjuvant. Others, however, have
recently reported that the same protein can elicit protective effects
when administered in Freund’s adjuvant, but additionally observed
strong effects on parasitaemia with an adjuvant-only control (Man
et al., 2017); further work will therefore be required to resolve
these effects. It is also likely that an effective blood stage vaccine
will contain multiple components, each targeting a different stage
of the erythrocyte invasion process, a strategy that seems effective
for P. falciparum (Bustamante et al., 2017) and already suggested
for B. microti (Wang et al., 2017). Similarly, where potential vaccine
antigens exhibit geographically restricted sequence variation, it
could be the case that certain antigens may be less effective in
some regions, similar to what has been described for P. falciparum
(Takala and Plowe, 2009). The economic case to invest in future
research to develop a vaccine, however, must be continually bal-
anced against other treatment options such as the development
of new drugs, tick and deer control, as well as the relatively small
potential market size. Our library of B. microti proteins identified
from the genome sequence now provides a wider selection of anti-
gens that can be systematically tested for vaccine candidacy.
In summary, we have compiled a library of recombinant pro-
teins produced in a mammalian expression system that represent
the cell surface repertoire and secreted proteins of the blood stage
of B. microti. We envisage that, together with the availability of a
murine B. microti infection model, these proteins could be system-
atically tested using a ‘‘reverse vaccinology” approach to identify
potential vaccine candidates as well as informative serological
Fig. 5. The Babesia microti major coat protein adjuvanted in alhydrogel does not affect the pathology of murine infections. (A) The B. microti BmSA1 and control Plasmodium
falciparum circumsporozoite protein were purified and resolved by SDS-PAGE under reducing conditions and visualised using Coomassie staining. The proteins resolved as
single bands, demonstrating they were >95% pure. (B) Quantification of the elicited antibody titres in mice immunised with either BmSA1 or control CSP recombinant
proteins. Sera from individual mice were serially diluted and their immunoreactivity quantified by ELISA against the corresponding biotinylated protein immobilised in
individual wells of a streptavidin-coated microtitre plate. Antibody responses to the hexa-His and enzymatically biotinylatable peptide sequences were determined by using
an unrelated control protein containing the same protein tags (tag controls). Data points represent means ± S.D.; n = 13 (BmSA1); n = 12 circumsporozoite protein. (C)
Schematic showing the immunisation schedule: 9-week-old female BALB/c mice were immunised three times with either BmSA1 or control circumsporozoite protein as
indicated and rested for 4 weeks before challenging with B. microti LS1 strain. (D) Parasitaemia is quantified as the percentage of infected RBCs in BmSA1 (n = 13) and control
CSP-vaccinated (n = 12) mice followed the same kinetics, suggesting no protective effects of antibodies to BmSA1.
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diagnostic markers. Beyond these clinical applications, we also
believe that these proteins will be a valuable resource to investi-
gate the basic biology of the parasite and especially the molecular
basis of erythrocyte recognition and invasion by Babesia spp. para-
sites, of which very little is currently known.
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